CN104523675A - Application of curcuma zedoary epoxy ketone in preparation of medicine or food for preventing and treating psoriasis - Google Patents
Application of curcuma zedoary epoxy ketone in preparation of medicine or food for preventing and treating psoriasis Download PDFInfo
- Publication number
- CN104523675A CN104523675A CN201510036969.9A CN201510036969A CN104523675A CN 104523675 A CN104523675 A CN 104523675A CN 201510036969 A CN201510036969 A CN 201510036969A CN 104523675 A CN104523675 A CN 104523675A
- Authority
- CN
- China
- Prior art keywords
- epoxy ketone
- rhizoma curcumae
- food
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 21
- 235000013305 food Nutrition 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 240000009138 Curcuma zedoaria Species 0.000 title abstract description 9
- 235000003405 Curcuma zedoaria Nutrition 0.000 title description 3
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 title description 3
- 235000019509 white turmeric Nutrition 0.000 title description 3
- 244000164480 Curcuma aromatica Species 0.000 title description 2
- 235000014375 Curcuma Nutrition 0.000 title 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 239000012453 solvate Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000010828 elution Methods 0.000 claims description 21
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000007791 liquid phase Substances 0.000 claims description 5
- 239000012071 phase Substances 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 238000010189 synthetic method Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 3
- 206010042971 T-cell lymphoma Diseases 0.000 abstract description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract description 2
- 229920000832 Cutin Polymers 0.000 abstract 1
- 210000002615 epidermis Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000000452 restraining effect Effects 0.000 abstract 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000006481 glucose medium Substances 0.000 description 4
- CVIVANCKIBYAOP-WSQYCBKMSA-N (3R,5S,8E)-5,9,14-Trimethyl-4,12-dioxatricyclo[9.3.0.03,5]tetradeca-1(11),8,13-trien-2-one Chemical compound C1\C(C)=C\CC[C@]2(C)O[C@H]2C(=O)C2=C1OC=C2C CVIVANCKIBYAOP-WSQYCBKMSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- MCBCRNSGLGHFSE-UHFFFAOYSA-N zederone Natural products CC1=C/CCC2(C)OC2C(=O)C3C(C1)OC=C3C MCBCRNSGLGHFSE-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000028280 polygenic inheritance Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to the technical field of psoriasis prevention and treatment, and discloses application of curcuma zedoary epoxy ketone in preparation of a medicine or food for preventing and treating psoriasis. The medicine contains at least one of curcuma zedoary epoxy ketone, and pharmaceutical salt and solvate of the curcuma zedoary epoxy ketone. The invention further provides a method for extracting curcuma zedoary epoxy ketone from root stocks of curcuma zedoary. The application of the curcuma zedoary epoxy ketone in preparation of the medicine or food for preventing and treating psoriasis disclosed by the invention is mainly reflected in the activity of restraining proliferation of HH cells of a human T cell lymphoma cell line and HaCaT cells of the immortalized epidermis cutin generation cell line.
Description
Technical field
The invention belongs to control psoriasis technical field, the particularly application of Rhizoma Curcumae epoxy ketone in preparation control psoriasis or food.
Background technology
Psoriasis (psiriasis) is a kind of that determined by polygenic inheritance, that multi-environment factor stimulates induction dysimmune chronic proliferative dermatoses.Its histo pathological change main manifestations is that keratinocyte hyperplasia, inflammatory cell infiltration and new vessels are formed.Complicated and the recurrent exerbation of the psoriasis cause of disease is the difficult medical problem in the puzzlement whole world always.At present, clinical conventional medicine mainly contains local topical medicine, systemic agent, biological preparation etc.External used medicine is only applicable to patients with mild, and systemic agent toxicity is large and be difficult to tolerance, and the expensive and safety of biological preparation needs long-term evaluation.It is study hotspot both domestic and external that exploitation treats psoriasis safely and effectively always.
Adopt application on human skin t cell lymphoma cell line HH cell and people's immortalization epidermal keratinocytes cellulation system HaCaT cell as medicaments sifting model in the present invention, in-vitro screening treats psoriatic drug candidate, find that Rhizoma Curcumae epoxy ketone (zederone) has the activity of the propagation of stronger suppression HTL cell line HH cell and people's immortalization epidermal keratinocytes cellulation system HaCaT cell, be expected to be applied in the medicine or food preparing curing psoriasis.There is not been reported for foregoing.Rhizoma Curcumae epoxy ketone (zederone) is known compound, and its CAS registration number is 7727-79-9, and structure is shown in formula 1.
Summary of the invention
In order to overcome the shortcoming of above-mentioned prior art with not enough, primary and foremost purpose of the present invention is to provide the application of Rhizoma Curcumae epoxy ketone in preparation control psoriasis or food.
Another object of the present invention is to the preparation method that a kind of above-mentioned Rhizoma Curcumae epoxy ketone is provided.
Object of the present invention is realized by following proposal:
The application of Rhizoma Curcumae epoxy ketone in preparation control psoriasis or food.
The application main manifestations of Rhizoma Curcumae epoxy ketone of the present invention in preparation control psoriasis or food is the propagation suppressing HTL's cell line HH cell and people's immortalization epidermal keratinocytes cellulation system HaCaT cell.
Described pharmaceutical pack contains at least one in Rhizoma Curcumae epoxy ketone, its pharmaceutical salts and its solvate.
Described medicine can contain one or more pharmaceutically acceptable carrier or excipient.
Described Rhizoma Curcumae epoxy ketone can from plant extract or synthetic method preparation.
Described synthetic method preparation refers to close cost compounds by the preparation method of this compound analog.
Described refers to carry out enriched compound from the secondary metabolites (natural product) of plant or microorganism from plant extract.
Such as adopt conventional plant chemical method to be separated from the rhizome of Zingiberaceae curcuma Guangxi zedoary, specifically comprise following preparation method:
(1) Rhizoma Curcumae rhizome is got, extract with 95% alcohol-water, extract is separated through HP-20 macroporous adsorbent resin column chromatography, successively with water, 30% ethanol, 90 ~ 100% ethanol gradient elutions, collect each eluent respectively, concentrating under reduced pressure, obtains water elution position, 30% alcohol elution, 90 ~ 100% alcohol elutions;
(2) 90 ~ 100% alcohol elutions of step (1) are got, be separated through silica gel column chromatography, use chloroform-methanol gradient elution, collect the fraction E that chloroform-methanol ratio is 9:1, fraction E, through ODS pillar layer separation, uses methanol-water gradient elution, collects the fraction E-6 that methanol-water ratio is 7:3, fraction E-6 is separated through preparation liquid phase HPLC, obtains Rhizoma Curcumae epoxy ketone.
In above-mentioned preparation method, step (2) described preparative liquid chromatography take volume ratio as the methanol-water of 65:35 is mobile phase, and determined wavelength is 208nm, and flow velocity is 12mL/min, and the retention time of Rhizoma Curcumae epoxy ketone in preparation liquid phase is 21.5min.
The present invention, relative to prior art, has following advantage and beneficial effect:
Rhizoma Curcumae epoxy ketone of the present invention has the activity suppressing HTL's cell line HH cell and people's immortalization epidermal keratinocytes cellulation system HaCaT cell proliferation, can be applicable in preparation control psoriasis or food.
Accompanying drawing explanation
Fig. 1 is that Rhizoma Curcumae epoxy ketone is to HTL cell line HH cell inhibitory effect design sketch.
Fig. 2 is that Rhizoma Curcumae epoxy ketone is to people's immortalization epidermal keratinocytes cellulation system HaCaT cell inhibitory effect design sketch.
Detailed description of the invention
Below in conjunction with embodiment and accompanying drawing, the present invention is described in further detail, but embodiments of the present invention are not limited thereto.
In embodiment, biological material source used is as follows:
DMEM high glucose medium, hyclone (FBS) are purchased from Hyclone company; Pancreatin Trypsin-EDTA is purchased from Gibco company; RPMI1640 high glucose medium, HTL cell line HH cell are purchased from ATCC company; Purchased from China typical culture collection center, (CCTCC numbers people's immortalization epidermal keratinocytes cellulation system HaCaT cell: GDC106); CCK-8 cytoactive detection kit is purchased from eastern Renhua subject skill (Shanghai) Co., Ltd..
Embodiment 1: the preparation of Rhizoma Curcumae epoxy ketone
Get dry Guangxi zedoary rhizome, (ethanol: water=95:5 is extracted with ethanol-water solution, v/v), extract is separated through HP-20 macroporous adsorbent resin column chromatography, successively with water, and 30% ethanol, 90 ~ 100% ethanol gradient elutions (each gradient eluent consumption 12L), collect each eluent respectively, concentrating under reduced pressure, obtain water elution position, 30% alcohol elution, 90 ~ 100% alcohol elutions, get 90 ~ 100% alcohol elutions, be separated through silica gel column chromatography, with chloroform-methanol gradient elution (each gradient eluent consumption 12L), collect the fraction E that chloroform-methanol ratio is 9:1, fraction E is through ODS pillar layer separation, use methanol-water gradient elution, collect the fraction E-6 that methanol-water ratio is 7:3, fraction E-6 is separated through preparation liquid phase HPLC, take volume ratio as the methanol-water of 65:35 be mobile phase, determined wavelength is 208nm, flow velocity is 12mL/min, retention time in preparation liquid phase is 21.5min, gained solution is dry, utilize high resolution mass spectrum (HR-ESI-MS), nuclear magnetic resonance, NMR (NMR) method, obtain Rhizoma Curcumae epoxy ketone 19.7mg.
Embodiment 2: Rhizoma Curcumae epoxy ketone vitro inhibition HTL cell line HH cell proliferation detects
1600rpm, 3min collected by centrifugation is in the HH cell of exponential phase, and with resuspended containing 10%FBSRPMI1640 high glucose medium; In 96 orifice plates, every hole adds the HH cell suspension of 100 μ L, is 2 × 10 to final concentration
4individual cell per well.Embodiment 1 is separated the Rhizoma Curcumae epoxy ketone obtained and is dissolved in DMSO, is configured to the storage liquid that final concentration is 10mM; During use, the storage liquid of getting 10 μ L joins in the RPMI1640 culture medium of 90 μ L, is diluted to the use liquid of 1mM; Meanwhile, the DMSO getting 10 μ L joins in the RPMI1640 culture medium of 90 μ L as negative controls.The use liquid getting 0,1,2,2.5,3,3.5,5,10 μ L is respectively added in 96 orifice plates the Concentraton gradient making 0,10,20,25,30,35,50,100 μM; Meanwhile, negative control group adds the negative controls of respective volume.37 DEG C, 5%CO
2cultivate 24h in incubator, every hole adds the CCK-8 of 10 μ L, and in incubator, lucifuge cultivates 4h, uses microplate reader to measure the light absorption value of 450nm, conversion suppression ratio, uses the mapping of Graphpad software, the results are shown in Figure 1.
Suppression ratio %=[1-(experimental group OD/ matched group OD)] × 100%
As seen from Figure 1, by using CCK8 kit measurement cell viability, can find, compared with negative control group, after the process of Rhizoma Curcumae epoxy ketone, HH cell proliferation receives suppression.
Embodiment 3: Rhizoma Curcumae epoxy ketone vitro inhibition people immortalization epidermal keratinocytes cellulation system HaCaT cell proliferation detects
Pancreatin Trypsin-EDTA digestion is used to be in the HaCaT cell of exponential phase; 1600rpm, 3min collected by centrifugation, and resuspended with the DMED high glucose medium containing 10%FBS; In 96 orifice plates, every hole adds the cell suspension of 100 μ L, is 5000, every hole cell to final concentration; 37 DEG C, 5%CO
212h is cultivated in incubator; By the method for embodiment 2, the use liquid getting different volumes is added in 96 orifice plates the Concentraton gradient making 0,10,20,25,30,35,50,100 μM; Meanwhile, negative control group adds the negative controls of respective volume.37 DEG C, 5%CO
2cultivate 24h in incubator, every hole adds the CCK-8 of 10 μ L, and in incubator, lucifuge cultivates 4h, uses microplate reader to measure the light absorption value of 450nm, conversion suppression ratio, uses the mapping of Graphpad software, the results are shown in Figure 2.
Suppression ratio %=[1-(experimental group OD/ matched group OD)] × 100%
As seen from Figure 2, by using CCK8 kit measurement cell viability, can find, after the process of Rhizoma Curcumae epoxy ketone, HaCaT cell proliferation receives suppression.
Above-described embodiment is the present invention's preferably embodiment; but embodiments of the present invention are not restricted to the described embodiments; change, the modification done under other any does not deviate from spirit of the present invention and principle, substitute, combine, simplify; all should be the substitute mode of equivalence, be included within protection scope of the present invention.
Claims (6)
1. the application of Rhizoma Curcumae epoxy ketone in preparation control psoriasis or food.
2. the application of Rhizoma Curcumae epoxy ketone according to claim 1 in preparation control psoriasis or food, is characterized in that: described pharmaceutical pack contains at least one in Rhizoma Curcumae epoxy ketone, its pharmaceutical salts and its solvate.
3. the application of Rhizoma Curcumae epoxy ketone according to claim 1 in preparation control psoriasis or food, is characterized in that: described medicine contains one or more pharmaceutically acceptable carrier or excipient.
4. the application of Rhizoma Curcumae epoxy ketone according to claim 1 in preparation control psoriasis or food, is characterized in that: described Rhizoma Curcumae epoxy ketone is from plant extract or synthetic method preparation.
5. the application of Rhizoma Curcumae epoxy ketone according to claim 1 in preparation control psoriasis or food, is characterized in that: described Rhizoma Curcumae epoxy ketone is prepared by the method specifically comprised the following steps:
(1) Rhizoma Curcumae rhizome is got, extract with 95% alcohol-water, extract is separated through HP-20 macroporous adsorbent resin column chromatography, successively with water, 30% ethanol, 90 ~ 100% ethanol gradient elutions, collect each eluent respectively, concentrating under reduced pressure, obtains water elution position, 30% alcohol elution, 90 ~ 100% alcohol elutions;
(2) 90 ~ 100% alcohol elutions of step (1) are got, be separated through silica gel column chromatography, use chloroform-methanol gradient elution, collect the fraction E that chloroform-methanol ratio is 9:1, fraction E, through ODS pillar layer separation, uses methanol-water gradient elution, collects the fraction E-6 that methanol-water ratio is 7:3, fraction E-6 is separated through preparation liquid phase HPLC, obtains Rhizoma Curcumae epoxy ketone.
6. the application of Rhizoma Curcumae epoxy ketone according to claim 5 in preparation control psoriasis or food, it is characterized in that: step (2) described preparative liquid chromatography, take volume ratio as the methanol-water of 65:35 be mobile phase, determined wavelength is 208nm, and flow velocity is 12mL/min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510036969.9A CN104523675A (en) | 2015-01-23 | 2015-01-23 | Application of curcuma zedoary epoxy ketone in preparation of medicine or food for preventing and treating psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510036969.9A CN104523675A (en) | 2015-01-23 | 2015-01-23 | Application of curcuma zedoary epoxy ketone in preparation of medicine or food for preventing and treating psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104523675A true CN104523675A (en) | 2015-04-22 |
Family
ID=52839434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510036969.9A Pending CN104523675A (en) | 2015-01-23 | 2015-01-23 | Application of curcuma zedoary epoxy ketone in preparation of medicine or food for preventing and treating psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104523675A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106946981A (en) * | 2017-03-08 | 2017-07-14 | 南京师范大学 | A kind of tetrapeptide propylene oxide derivatives and its production and use |
| CN109331008A (en) * | 2018-12-11 | 2019-02-15 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Application of the rcumenol in the drug of preparation prevention and treatment psoriasis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173907A (en) * | 2013-05-20 | 2014-12-03 | 广州中医药大学第二附属医院 | Application of zedoary turmeric oil in preparation of psoriasis treatment medicines |
-
2015
- 2015-01-23 CN CN201510036969.9A patent/CN104523675A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173907A (en) * | 2013-05-20 | 2014-12-03 | 广州中医药大学第二附属医院 | Application of zedoary turmeric oil in preparation of psoriasis treatment medicines |
Non-Patent Citations (2)
| Title |
|---|
| 宋智琦等: "外用莪术油霜剂治疗银屑病", 《中华皮肤科杂志》 * |
| 翁维良: "《临床中医学》", 31 May 1998, 河南科学技术出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106946981A (en) * | 2017-03-08 | 2017-07-14 | 南京师范大学 | A kind of tetrapeptide propylene oxide derivatives and its production and use |
| CN106946981B (en) * | 2017-03-08 | 2020-08-21 | 南京陵瑞医药科技有限公司 | Tetrapeptide epoxypropane derivative and preparation method and application thereof |
| CN109331008A (en) * | 2018-12-11 | 2019-02-15 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Application of the rcumenol in the drug of preparation prevention and treatment psoriasis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Identification of the toxic constituents in Rhizoma Coptidis | |
| Chen et al. | In vivo study of four preparative extracts of Clematis terniflora DC. for antinociceptive activity and anti-inflammatory activity in rat model of carrageenan-induced chronic non-bacterial prostatitis | |
| CN101240005A (en) | Method for preparing platycodin D from balloon-flower root and application thereof in anti-cancer medicament | |
| CN115154476A (en) | Cyclocarya paliurus extract and application thereof in resisting gout and reducing uric acid | |
| CN101810653A (en) | Application of wild sesame seed extract in preparation of anti-hepatic fibrosis medicament | |
| CN104523675A (en) | Application of curcuma zedoary epoxy ketone in preparation of medicine or food for preventing and treating psoriasis | |
| CN103360456B (en) | Triterpene compound and Synthesis and applications | |
| CN105726524A (en) | Use of diarylheptanoid compound in preparation of drug or food for preventing and treating psoriasis | |
| CN101028322B (en) | Use of Maoliefengdou extract for preparing anti-cancer medicine | |
| CN102309542A (en) | Orthosiphon n-butanol fraction medicine for treating chronic nephritis and preparation method thereof | |
| Gan et al. | Protective effects of isorhynchophylline on cardiac arrhythmias in rats and guinea pigs | |
| CN105732380B (en) | A kind of diphenyl heptane compound and its preparation method and application | |
| CN103288914B (en) | Preparation method of traditional Chinese medicine manyflower tickclove herb extract and application in anti-senile dementia medicaments | |
| CN101953842B (en) | Application of syringin in preparation of medicine for treating acute gout | |
| CN108997453B (en) | Diphenyl ethyl ketone glycoside compound and preparation method and application thereof | |
| CN102675270B (en) | Method for extracting anticancer compound from henbane, and application of anticancer compound | |
| CN102311476B (en) | Toonapubesin C and preparation method as well as application thereof | |
| CN107468684B (en) | It ellagic acid and is cooperateed with Celastrol and is preparing the application in anti-lung-cancer medicament | |
| CN105213364B (en) | The application of khellactone | |
| CN107281178B (en) | Application of Corylifol A in preparation of anti-radiation medicine | |
| CN100545163C (en) | Traditional Chinese medicine active ingredient compound for preventing and treating senile dementia and preparation and application thereof | |
| CN108997473A (en) | A kind of non-sea cucumber alkane type selenka and the preparation method and application thereof | |
| CN103113196A (en) | Glechoma longituba phenol, and preparation method and application thereof | |
| CN105732379B (en) | A kind of diphenyl heptane compound and its preparation method and application | |
| CN105363031B (en) | The purposes of α-(8- quinoline oxy) mono-substituted zinc phthalocyanine treatment psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |